NEWS

Skymab Biotherapeutics has been selected among the 10 laureates of the Paris-Saclay Cancer Cluster (PSCC) BOOST Grant, a highly competitive program supporting breakthrough oncology innovations.

The award recognizes the potential of Skymab’s next-generation ADC platform and will accelerate key translational, regulatory and partnering milestones toward clinical development.

Skymab participated in BioSpring Europe 2026 to engage with international investors and pharmaceutical companies and explore strategic collaborations supporting the development of its next-generation ADC pipeline and platform technologies.

Skymab chaired scientific sessions dedicated to next-generation GPCR therapeutics and ADC innovation, contributing to discussions on emerging technologies addressing difficult-to-drug targets and precision oncology.

Skymab presented the latest advances of its next-generation ADC platform at World ADC London 2026, highlighting progress toward IND-enabling studies for SKM104 and the continued expansion of the SKYLINK™ technology platform.

The conference provided valuable opportunities to engage with global pharmaceutical partners and the international ADC community.

Skymab opened the 14th Tumour Models Summit as Conference Chair and Expert Speaker, joining leading scientists from AstraZeneca, Roche, Ipsen, Merck and other organizations to discuss next-generation translational oncology models accelerating drug development.

Skymab chaired the Advancing Large Molecule Drug Discovery scientific track and presented its strategy for overcoming resistance mechanisms in antibody-drug conjugate therapies through innovative target biology and the proprietary SKYLINK™ platform.

Skymab presented new preclinical data demonstrating the efficacy and safety profile of SKM104, its first-in-class anti-GPCR ADC, in pancreatic ductal adenocarcinoma.

These findings further support the broad therapeutic potential of the SKM104 program across difficult-to-treat cancers.

Skymab chaired the Clinical GPCR session and participated in expert roundtable discussions focused on emerging GPCR-targeted therapeutic modalities, including ADCs and radioconjugates.
The meeting provided an opportunity to exchange with international experts and pharmaceutical partners advancing precision oncology.

Skymab presented the poster:
“GPCR1 as a New Biomarker and ADC Target in Triple-Negative Breast Cancer.”
The presentation highlighted GPCR1 as a promising biomarker and therapeutic target, supporting the development of differentiated precision oncology therapies.

Skymab presented SKM104 during the Translational Preclinical stream, showcasing compelling efficacy and safety data supporting its progression toward IND-enabling studies.
The meeting also provided opportunities to engage with leading ADC developers, pharmaceutical companies and strategic partners.